Page 1

News Release Fisher & Paykel HEALTHCARE STOCK EXCHANGE LISTINGS : NEW ZEALAND ( FPH ) , AUSTRALIA ( FPH ) Fisher & Paykel Healthcare Provides FY22 Trading Update Auckland , New Zealand , 18 August 2021 – Fisher & Paykel Healthcare Corporation Limited has provided an update on the first four months of the 2022 financial year , which ended 31 July 2021 . The company is holding a virtual - only annual shareholders ' meeting today at 2pm . Revenue for the first four months was $ 583M , with 74 % of revenue from the company's Hospital product group and 26 % from its Homecare product group . In constant currency , revenue for the four months was 2 % below the prior comparable period , which was a period of high demand during the initial surges of COVID - 19 in North America and Europe . Managing Director and CEO Lewis Gradon said , " We would like to express our gratitude for the incredible efforts of healthcare professionals who are caring for patients during another difficult year . " We would also like to acknowledge the people of Fisher & Paykel Healthcare working behind the scenes in our manufacturing facilities , warehouses , offices and at home to meet the ongoing global demand for respiratory products during the pandemic , " said Gradon . Hospital product group In the company's Hospital product group , constant currency revenue for the four months of the 2022 financial year was 3 % below the prior comparable period . This consisted of a 13 % decline in hardware sales , partially offset by 2 % growth in consumables . For the four months ended 31 July 2021 : • • 66 % of Hospital revenue was from the sale of consumables , and 34 % was from hardware sales . Compared to pre - COVID - 19 levels , overall hardware volume remained elevated , largely driven by some regions experiencing COVID - 19 hospitalisation surges during the period . • In North America and Europe , total hardware sales declined 62 % and total consumables sales declined 14 % from the prior comparable period , in constant currency , influenced by reduced COVID - 19 hospital admissions and customers ' stockholding decisions . Compared with pre- COVID - 19 levels , sales volumes in North America and Europe remained elevated . • Outside North America and Europe , hardware grew 42 % and consumables grew 31 % over the prior comparable period in constant currency . • The company's Hospital consumables sales continue to reflect the clinical practice shift from invasive ventilation toward the use of Optiflow ™ nasal high flow therapy , as demonstrated by new applications consumables growth of 17 % in constant currency . Homecare product group In the company's Homecare product group , constant currency revenue for the four months ended 31 July 2021 was 4 % above the prior comparable period , with 4 % growth in obstructive sleep apnea ( OSA ) masks .